Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free MGEN Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Miragen Therapeutics (MGEN) Competitors

Miragen Therapeutics logo
Compare

MGEN vs. TENX, VYGR, LFMD, FENC, and SGHT

Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Tenax Therapeutics (TENX), Voyager Therapeutics (VYGR), LifeMD (LFMD), Adherex Technologies (FENC), and Sight Sciences (SGHT). These companies are all part of the "medical" sector.

How does Miragen Therapeutics compare to Tenax Therapeutics?

Miragen Therapeutics (NASDAQ:MGEN) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

1.7% of Tenax Therapeutics shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by insiders. Comparatively, 3.1% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tenax Therapeutics has a net margin of 0.00% compared to Miragen Therapeutics' net margin of -1,393.50%. Tenax Therapeutics' return on equity of -51.83% beat Miragen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Miragen Therapeutics-1,393.50% -141.66% -88.74%
Tenax Therapeutics N/A -51.83%-49.51%

Miragen Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46M12.68-$41.87M-$20.09N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.33N/A

Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

In the previous week, Tenax Therapeutics had 5 more articles in the media than Miragen Therapeutics. MarketBeat recorded 5 mentions for Tenax Therapeutics and 0 mentions for Miragen Therapeutics. Tenax Therapeutics' average media sentiment score of 0.34 beat Miragen Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Miragen Therapeutics Neutral
Tenax Therapeutics Neutral

Tenax Therapeutics has a consensus price target of $29.67, indicating a potential upside of 154.43%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Tenax Therapeutics beats Miragen Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Miragen Therapeutics compare to Voyager Therapeutics?

Miragen Therapeutics (NASDAQ:MGEN) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

48.0% of Voyager Therapeutics shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Voyager Therapeutics has a net margin of -296.53% compared to Miragen Therapeutics' net margin of -1,393.50%. Voyager Therapeutics' return on equity of -51.35% beat Miragen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Miragen Therapeutics-1,393.50% -141.66% -88.74%
Voyager Therapeutics -296.53%-51.35%-39.38%

Miragen Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Miragen Therapeutics$4.46M12.68-$41.87M-$20.09N/A
Voyager Therapeutics$40.37M6.06-$119.72M-$2.03N/A

Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

In the previous week, Voyager Therapeutics had 4 more articles in the media than Miragen Therapeutics. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for Miragen Therapeutics. Voyager Therapeutics' average media sentiment score of 0.19 beat Miragen Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Miragen Therapeutics Neutral
Voyager Therapeutics Neutral

Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 307.41%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

Voyager Therapeutics beats Miragen Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Miragen Therapeutics compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

LifeMD presently has a consensus price target of $9.14, indicating a potential upside of 91.27%. Given LifeMD's stronger consensus rating and higher probable upside, research analysts plainly believe LifeMD is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

LifeMD has higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$194.05M1.17$14.35M$0.2618.38
Miragen Therapeutics$4.46M12.68-$41.87M-$20.09N/A

LifeMD has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

LifeMD has a net margin of 2.37% compared to Miragen Therapeutics' net margin of -1,393.50%. Miragen Therapeutics' return on equity of -141.66% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMD2.37% -176.40% -22.61%
Miragen Therapeutics -1,393.50%-141.66%-88.74%

35.5% of LifeMD shares are owned by institutional investors. 18.4% of LifeMD shares are owned by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, LifeMD had 13 more articles in the media than Miragen Therapeutics. MarketBeat recorded 13 mentions for LifeMD and 0 mentions for Miragen Therapeutics. Miragen Therapeutics' average media sentiment score of 0.00 beat LifeMD's score of -0.15 indicating that Miragen Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
LifeMD Neutral
Miragen Therapeutics Neutral

Summary

LifeMD beats Miragen Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Miragen Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Adherex Technologies presently has a consensus price target of $14.80, indicating a potential upside of 113.56%. Given Adherex Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Adherex Technologies is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Adherex Technologies has higher revenue and earnings than Miragen Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M5.36-$9.74M-$0.34N/A
Miragen Therapeutics$4.46M12.68-$41.87M-$20.09N/A

Adherex Technologies has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Adherex Technologies has a net margin of -22.62% compared to Miragen Therapeutics' net margin of -1,393.50%. Miragen Therapeutics' return on equity of -141.66% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies-22.62% -183.18% -15.31%
Miragen Therapeutics -1,393.50%-141.66%-88.74%

55.5% of Adherex Technologies shares are owned by institutional investors. 11.8% of Adherex Technologies shares are owned by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Adherex Technologies had 6 more articles in the media than Miragen Therapeutics. MarketBeat recorded 6 mentions for Adherex Technologies and 0 mentions for Miragen Therapeutics. Adherex Technologies' average media sentiment score of 0.23 beat Miragen Therapeutics' score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Adherex Technologies Neutral
Miragen Therapeutics Neutral

Summary

Adherex Technologies beats Miragen Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Miragen Therapeutics compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

55.5% of Sight Sciences shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sight Sciences presently has a consensus price target of $8.31, indicating a potential upside of 54.51%. Given Sight Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Sight Sciences is more favorable than Miragen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Miragen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Sight Sciences has higher revenue and earnings than Miragen Therapeutics. Sight Sciences is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$77.36M3.78-$38.43M-$0.75N/A
Miragen Therapeutics$4.46M12.68-$41.87M-$20.09N/A

Sight Sciences has a net margin of -46.83% compared to Miragen Therapeutics' net margin of -1,393.50%. Sight Sciences' return on equity of -49.92% beat Miragen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-46.83% -49.92% -28.00%
Miragen Therapeutics -1,393.50%-141.66%-88.74%

In the previous week, Sight Sciences had 9 more articles in the media than Miragen Therapeutics. MarketBeat recorded 9 mentions for Sight Sciences and 0 mentions for Miragen Therapeutics. Miragen Therapeutics' average media sentiment score of 0.00 beat Sight Sciences' score of -0.25 indicating that Miragen Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Sight Sciences Neutral
Miragen Therapeutics Neutral

Summary

Sight Sciences beats Miragen Therapeutics on 13 of the 16 factors compared between the two stocks.

Get Miragen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGEN vs. The Competition

Export
MetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$56.55M$6.47M$6.18B$12.29B
Dividend YieldN/AN/A2.78%5.25%
P/E Ratio-1.36N/A28.7027.27
Price / Sales12.682.87506.8864.14
Price / CashN/AN/A43.3053.97
Price / Book2.130.1110.006.82
Net Income-$41.87M-$21.55M$3.54B$332.87M

Miragen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGEN
Miragen Therapeutics
N/A$14.47
+3.7%		N/A+20.3%$56.55M$4.46MN/A45
TENX
Tenax Therapeutics
2.0752 of 5 stars		$12.78
-2.5%		$29.67
+132.1%		+109.2%$225.46MN/AN/A9
VYGR
Voyager Therapeutics
2.3986 of 5 stars		$3.76
+0.8%		$16.50
+338.8%		+20.7%$225.35M$40.37MN/A100
LFMD
LifeMD
3.5653 of 5 stars		$5.00
+6.8%		$9.14
+82.9%		-44.1%$224.52M$194.05M19.23230
FENC
Adherex Technologies
3.794 of 5 stars		$6.54
+0.8%		$14.80
+126.3%		+12.9%$224.17M$44.64MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MGEN) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel